Gilead tags Merck for first-line triple negative breast cancer trial
pharmaphorum
OCTOBER 29, 2021
Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? Gilead is sponsoring the new study to see if adding Trodelvy can be an alternative chemo when added to Keytruda in the first-line treatment of advanced TNBC, in the hope of moving the ADC up the treatment pathway.
52 
Let's personalize your content